The Biostatistics Core provides OSUCCC investigators with a centralized resource offering expertise in the statistical aspects of clinical research, basic research and cancer prevention and control Statistical issues are addressed at all levels of investigation; from the design of experiments, to the maintenance of data quality, and to the descriptive and inferential statements made from the collected data.
Specific aims of this core resource include: 1) to collaborate with CCC investigators in reviewing and determining experimental designs for both clinical and basic research, 2) to conduct and direct the statistical analysis of data generated by CCC- supported studies including both descriptive summary statistical analysis of data generated by CC-supported studies including both descriptive summary statistics as well as more sophisticated inferential procedures, 3) to provide assistance in developing and implementing data management systems to allow investigators to effective and efficiently manage and analyze their data, 4) to support the development and enhancement of the CCC's clinical research information system to meet new needs of investigators and the changing nature of clinical research, 5) to assist with the integration of the clinical information system into the OSU Hospitals' computer network such that data may be shared among data sources and that information on all patients being treated for cancer is available to investigators, 6) to coordinate the development of new statistical methodologies, when needed, to directly support research programs of the cancer c enter, 7) to ensure that statistical issues are addressed in CCC program decisions and directions, and 8) to conduct and participate in educational programs of cancer biostatistics for investigators, faculty, students, and staff. The Biostatistics Core has seen great changes and expansion in the past year to support growing CCC programs; the Core was restructured under the OSU Biostatistics Program, Dr. Stanley Lemeshow was appointed director, institutional support was provided for genetics statisticians, and added support was provided for Masters-level statisticians. In response to the past CCSG review, 1) biostatistical approval is required for all clinical protocols, 2) local, investigator- initiated studies are required to have biostatistical co-authors, 3) biostatisticians are included as named co-investigators on external grant submissions, 4) biostatistical involvement in basic programs is increased, and 5) chargeback policies and mechanisms are in place.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-26
Application #
6430840
Study Section
Project Start
2001-03-07
Project End
2001-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications